Skip to Main Content

Paper Details

Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study.
ESMO Open
20
2022
Author NameAffiliation
Young Mog ShimSamsung Medical Center, Sungkyunkwan University School of Medicine
  • 1 - 1

Datasets

Release 1.2